ABT stock: buy or sell?
August 22nd, 2019
Should I buy ABT stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Abbott Laboratories stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Abbott Laboratories stock a buy?
Financial institutions and banks publish stock ratings everyday.At Stocks2.com, we collected 15 ratings published for ABT stock in the last 30 days. The general sentiment of these ratings is bullish for ABT stock, with 12 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-14||BMO Capital Markets||n/a||n/a|
|2019-7-18||Jefferies Financial Group||n/a||Buy|
|2019-7-18||BMO Capital Markets||n/a||Outperform|
|2019-6-13||Wells Fargo & Co||n/a||Outperform|
|2019-6-13||Bank of America||n/a||Buy|
|2019-4-15||Royal Bank of Canada||n/a||Buy|
|2019-3-14||Wells Fargo & Co||n/a||Buy|
|2019-2-7||Bank of America||Buy||Buy|
ABT stock analysis
Shares of Abbott Laboratories closed today at $84.37 and slightly fell an ugly -0.62%.
Shares of Abbott Laboratories closed today at $84.37 and slightly fell an ugly -0.62%. ABT is soaring again after a 4.11% correction from its last top on Aug 13th at $87.10. Since June when ABT stock price broke up the SMA100d line, it gained $8.94 (11.85%). On Jul/23, ABT hit a new all time high, pushing higher than on July 22nd tops. Check different trading setups that use ATHs as triggers.
Abbott Laboratories declined an unpleasant -0.48% this week.
ABT shows a long term strength with several rising tops and rising bottoms. It left a new bottom at $82.31 early August. Previous top ($88.76) will play as a resistance in possible new gains. Not so far away is the last price record Abbott Laboratories marked late July. Since early June when ABT stock price broke up the SMA20w line, it gained $8.52 (11.23%).
ABT stock price history
ABT stock went public on March 17th, 1980 with a price of $0.201. Since then, ABT stock surged a 42,085.00%, with a yearly average of 1,079.10%. If you had invested $1,000 in ABT stock in 1980, it would worth $420,850.00 today.
1: Adjusted price after possible price splits or reverse-splits.
ABT stock historical price chart
ABT stock reached all-time highs on July 23rd with a price of $88.76.
ABT stock price target is $90.20Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We have 11 price forecasts for ABT stock released in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-18||Raymond James||Raises Target||$87.00||$93.00||6.9%|
|2019-7-18||Jefferies Financial Group||Raises Target||$80.00||$98.00||22.5%|
|2019-7-18||BMO Capital Markets||Raises Target||n/a||$94.00||-|
|2019-7-16||Morgan Stanley||Raises Target||$85.00||$93.00||9.4%|
|2019-6-13||Wells Fargo & Co||Raises Target||$89.00||$91.00||2.2%|
|2019-6-13||Bank of America||Raises Target||$81.00||$90.00||11.1%|
|2019-4-15||Royal Bank of Canada||Raises Target||n/a||$82.00||-|
|2019-2-7||Bank of America||Reiterates||$73.00||$81.00||11%|
|2019-1-2||Morgan Stanley||Raises Target||$82.00||$85.00||3.7%|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince April, when Abbott Laboratories posted its last earnings report, it escalated a more than good 9.27%. Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Abbott Laboratories annual sales rocketed a cool 11.64% to $30,578.00 million dollars from $27,390.00 marked in 2017. In contrast, its earnings margin (compared to sales) escalated to 7.74%, that is $2,368.00 million. Abbott Laboratories presents anual results in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Abbott Laboratories TTM sales up to March 2019 were $30,723.00 and earnings $2,622.00 million USD. If we compare this TTM figures with the last reported annuality, we can review Abbott Laboratories business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, stayed steady a tight 0.47%. In line, profit margin (net income/sales) remained stable at 7.74%.
|2013||$19,660 M||-||$1,970 M10.0%||-|
|2014||$20,247 M||2.99%||$2,284 M11.3%||15.94%|
|2015||$20,405 M||0.78%||$4,423 M21.7%||93.65%|
|2016||$20,853 M||2.20%||$1,400 M6.7%||-68.35%|
|2017||$27,390 M||31.35%||$477 M1.7%||-65.93%|
|2018||$30,578 M||11.64%||$2,368 M7.7%||396.44%|
|TTM||$30,723 M||0.47%||$2,622 M8.5%||10.73%|
Quarterly financial resultsAbbott Laboratories posted $7,535.00 million in sales for 2019-Q1, a -2.96% less compared to previous quarter. Reported quarter income marked $672.00 M with a profit margin of 8.92%. Profit margin stayed steady a 0.50% compared to previous quarter when profit margin was 8.42%. When comparing sales to same quarter last year, Abbott Laboratories sales marked a slightly fine growth and stepped up a 1.96%.
|2017-Q2||$6,640 M||-||$269 M4.1%||-|
|2017-Q3||$6,830 M||2.86%||$558 M8.2%||107.43%|
|2017-Q4||$7,589 M||11.11%||$-828 M-10.9%||-248.39%|
|2018-Q1||$7,390 M||-2.62%||$418 M5.7%||-150.48%|
|2018-Q2||$7,767 M||5.10%||$733 M9.4%||75.36%|
|2018-Q3||$7,656 M||-1.43%||$563 M7.4%||-23.19%|
|2018-Q4||$7,765 M||1.42%||$654 M8.4%||16.16%|
|2019-Q1||$7,535 M||-2.96%||$672 M8.9%||2.75%|
Abbott Laboratories ownershipWhen you are planning to buy shares of a stock, it's worth to check its ownership structure.
Abbott Laboratories shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.72% of all shares.
In case of Abbott Laboratories stock, 76.49% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ABT stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$148.5 B||$78.0 B||$59.3 B||$13.5 B||$349.9 B|
|Total shares||1,760.0 M||1,630.0 M||1,390.0 M||268.1 M||2,660.0 M|
|Float shares||1,750.0 M||1,630.0 M||1,390.0 M||266.1 M||2,630.0 M|
|- Institutional holdings (%)||76.5%||75.0%||93.4%||99.7%||69.2%|
|- Insider holdings (%)||0.7%||0.1%||0.2%||0.3%||0.1%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Thursday, August 22nd, 2019|
|Day range||$83.64 - $85.30|
|Average true range||$1.90|
|50d mov avg||$85.14|
|100d mov avg||$81.16|
|200d mov avg||$76.74|
Abbott Laboratories performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We picked Bristol-Myers Squibb, Boston Scientific, Hologic, , Medtronic, Mylan, Pfizer and Thermo Fisher Scientific as the bechmarking frame for Abbott Laboratories stock.
|TMOThermo Fisher Sci...||2.41%||10.49%||18.85%|
Abbott Laboratories competitorsWe selected a few stocks to conform a list of Abbott Laboratories competitors to watch if you are interested in investing in ABT:
- Bristol-Myers Squibb (BMY)
- Boston Scientific (BSX)
- Hologic (HOLX)
- Medtronic (MDT)
- Mylan (MYL)
- Pfizer (PFE)
- Thermo Fisher Scientific (TMO)
Latest ABT stock news
- InvestorPlaceAbbott Laboratories Earnings: ABT Stock Surges on Guidance, Q2 BeatJuly 17, 2019
- Seeking AlphaAbbott Laboratories: A Solid Business For An Attractive ValuationMay 8, 2019
- InvestorPlaceAbbott Laboratories Earnings: ABT Stock Down After Q1 BeatApril 17, 2019
- InvestorPlaceAll Signals Are Positive for Buying Abbott LaboratoriesJanuary 22, 2019
- InvestorPlace3 Big Stock Charts for Friday: Incyte, Schlumberger and Abbott LaboratoriesJanuary 4, 2019